Vivodyne raised $40 million in Series A funding led by Khosla Ventures to enhance its AI-driven human predictive insights and open a new facility in San Francisco.
Vivodyne raised $40 million in Series A funding led by Khosla Ventures to enhance its AI-driven human predictive insights and open a new facility in San Francisco.
05/29/25, 1:49 PM
Location
philadelphiaMoney raised
$40 million
Industry
biotechnology
Round Type
series a
Investors
Mbx Capital, Bison Ventures, Cs Ventures, Kairos Ventures, Fortius Ventures, Helena Capital, Lingotto Investment Management, Khosla Ventures
Vivodyne has raised $40 million in Series A financing to scale its robotics and AI approach for testing on lab-grown human tissues. The new funding will help open a 23,000-square-foot facility in South San Francisco, significantly increasing preclinical human testing capacity. This initiative aims to replace animal testing, which often leads to a 95% failure rate in clinical trials. The investment was led by Khosla Ventures, with participation from several other investors.
Company Info
Location
philadelphia, pennsylvania, united states
Additional Info
Vivodyne is a biotechnology company that accelerates the development of more effective medicines by testing on thousands of lifelike, lab-grown human organ tissues at a time. Robots are used to grow and experiment on lab-grown human organs at massive scale, creating datasets of unparalleled realism and breadth to power a predictive AI platform technology. Vivodyne was founded by University of Pennsylvania bioengineers Andrei Georgescu and Dan Huh.